AbbVie (ABBV) 10-Q3 May 242024 Q1 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2024	Apr. 25, 2024
Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-35565
Entity Registrant Name	AbbVie Inc.
Entity Central Index Key	0001551152
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0375147
Entity Address, Address Line One	1 North Waukegan Road
Entity Address, City or Town	North Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	847
Local Phone Number	932-7900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,765,867,781
NEW YORK STOCK EXCHANGE, INC. \| Common stock
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.375 Senior Notes Due 2024
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.375% Senior Notes due 2024
Trading Symbol	ABBV24
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.250 Senior Notes Due 2024
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.250% Senior Notes due 2024
Trading Symbol	ABBV24B
NEW YORK STOCK EXCHANGE, INC. \| Sec 0.750 Senior Notes Due 2027
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	0.750% Senior Notes due 2027
Trading Symbol	ABBV27
NEW YORK STOCK EXCHANGE, INC. \| Sec 2.125 Senior Notes due 2028
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.125% Senior Notes due 2028
Trading Symbol	ABBV28
NEW YORK STOCK EXCHANGE, INC. \| Sec 2.625 Senior Notes Due 2028
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.625% Senior Notes due 2028
Trading Symbol	ABBV28B
NEW YORK STOCK EXCHANGE, INC. \| Sec 2.125 Senior Notes Due 2029
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.125% Senior Notes due 2029
Trading Symbol	ABBV29
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.250 Senior Notes due 2031
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.250% Senior Notes due 2031
Trading Symbol	ABBV31
CHICAGO STOCK EXCHANGE, INC \| Common stock
Entity Information
Security Exchange Name	CHX
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenues	$ 12,310	$ 12,225
Cost of products sold	4,094	3,986
Selling, general and administrative	3,315	3,039
Research and development	1,939	2,292
Acquired IPR&D and milestones	164	150
Other operating income	0	(10)
Total operating costs and expenses	9,512	9,457
Operating earnings	2,798	2,768
Interest expense, net	453	454
Net foreign exchange loss	4	35
Other expense, net	586	1,804
Earnings before income tax expense	1,755	475
Income tax expense	383	234
Net earnings	1,372	241
Net earnings attributable to noncontrolling interest	3	2
Net earnings attributable to AbbVie Inc.	$ 1,369	$ 239
Per share data
Basic earnings per share (in dollars per share)	$ 0.77	$ 0.13
Diluted earnings per share (in dollars per share)	$ 0.77	$ 0.13
Weighted-average basic shares outstanding (in shares)	1,769	1,770
Weighted-average diluted shares outstanding (in shares)	1,773	1,776

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,372	$ 241
Foreign currency translation adjustments, net of tax expense (benefit) of $(20) for the three months ended March 31, 2024 and $12 for the three months ended March 31, 2023	(396)	194
Net investment hedging activities, net of tax expense (benefit) of $57 for the three months ended March 31, 2024 and $(60) for the three months ended March 31, 2023	207	(224)
Pension and post-employment benefits, net of tax expense (benefit) of $1 for the three months ended March 31, 2024 and $14 for the three months ended March 31, 2023	10	38
Cash flow hedging activities, net of tax expense (benefit) of $7 for the three months ended March 31, 2024 and $(4) for the three months ended March 31, 2023	30	(41)
Other comprehensive loss	(149)	(33)
Comprehensive income	1,223	208
Comprehensive income attributable to noncontrolling interest	3	2
Comprehensive income attributable to AbbVie Inc.	$ 1,220	$ 206

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]
Foreign currency translation adjustments, tax expense (benefit)	$ (20)	$ 12
Net investment hedging activities, tax expense (benefit)	57	(60)
Pension and post-employment benefits, tax expense (benefit)	1	14
Cash flow hedging activities, tax expense (benefit)	$ 7	$ (4)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and equivalents	$ 18,067	$ 12,814
Short-term investments	2	2
Accounts receivable, net	11,949	11,155
Inventories	4,245	4,099
Prepaid expenses and other	4,608	4,932
Total current assets	38,871	33,002
Investments	305	304
Property and equipment, net	4,980	4,989
Intangible assets, net	62,225	55,610
Goodwill	33,426	32,293
Other assets	9,067	8,513
Total assets	148,874	134,711
Current liabilities
Short-term borrowings	3	0
Current portion of long-term debt and finance lease obligations	10,193	7,191
Accounts payable and accrued liabilities	31,326	30,650
Total current liabilities	41,522	37,841
Long-term debt and finance lease obligations	63,805	52,194
Deferred income taxes	2,722	1,952
Other long-term liabilities	32,778	32,327
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,829,957,662 shares issued as of March 31, 2024 and 1,823,046,087 as of December 31, 2023	18	18
Common stock held in treasury, at cost, 64,234,512 shares as of March 31, 2024 and 57,105,354 as of December 31, 2023	(7,829)	(6,533)
Additional paid-in capital	20,656	20,180
Accumulated deficit	(2,384)	(1,000)
Accumulated other comprehensive loss	(2,454)	(2,305)
Total stockholders' equity	8,007	10,360
Noncontrolling interest	40	37
Total equity	8,047	10,397
Total liabilities and equity	$ 148,874	$ 134,711

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,829,957,662	1,823,046,087
Treasury Stock, Common, Shares	64,234,512	57,105,354

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury Stock, Common	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss	Noncontrolling interest
Beginning balance at Dec. 31, 2022	$ 17,287	$ 18	$ (4,594)	$ 19,245	$ 4,784	$ (2,199)	$ 33
Beginning balance (in shares) at Dec. 31, 2022		1,769
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	239	$ 0	0	0	239	0	0
Other comprehensive income (loss), net of tax	(33)	0	0	0	0	(33)	0
Dividends declared	(2,630)	0	0	0	(2,630)	0	0
Purchases of treasury stock	(1,955)	$ 0	(1,955)	0	0	0	0
Purchases of treasury stock (in shares)		(12)
Stock-based compensation plans and other	399	$ 0	25	374	0	0	0
Stock-based compensation plans and other (in shares)		7
Change in noncontrolling interest	(4)	$ 0	0	0	0	0	(4)
Ending balance at Mar. 31, 2023	13,303	$ 18	(6,524)	19,619	2,393	(2,232)	29
Ending balance (in shares) at Mar. 31, 2023		1,764
Beginning balance at Dec. 31, 2023	10,397	$ 18	(6,533)	20,180	(1,000)	(2,305)	37
Beginning balance (in shares) at Dec. 31, 2023		1,766
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	1,369	$ 0	0	0	1,369	0	0
Other comprehensive income (loss), net of tax	(149)	0	0	0	0	(149)	0
Dividends declared	(2,753)	0	0	0	(2,753)	0	0
Purchases of treasury stock	(1,324)	$ 0	(1,324)	0	0	0	0
Purchases of treasury stock (in shares)		(7)
Stock-based compensation plans and other	504	$ 0	28	476	0	0	0
Stock-based compensation plans and other (in shares)		7
Change in noncontrolling interest	3	$ 0	0	0	0	0	3
Ending balance at Mar. 31, 2024	$ 8,047	$ 18	$ (7,829)	$ 20,656	$ (2,384)	$ (2,454)	$ 40
Ending balance (in shares) at Mar. 31, 2024		1,766

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Cash Flows [Abstract]
Net earnings	$ 1,372	$ 241
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	183	179
Amortization of intangible assets	1,891	1,948
Deferred income taxes	(389)	(267)
Change in fair value of contingent consideration liabilities	660	1,872
Payment for Contingent Consideration Liability, Operating Activities	(391)	(14)
Stock-based compensation	348	313
Acquired IPR&D and milestones	164	150
Impairment of intangible assets	0	710
Other, net	(45)	(128)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(702)	(195)
Inventories	(75)	(185)
Prepaid expenses and other assets	284	(167)
Accounts payable and other liabilities	362	(451)
Income tax assets and liabilities, net	378	187
Cash flows from operating activities	4,040	4,193
Cash flows from investing activities
Payments to Acquire Businesses, Net of Cash Acquired	(9,199)	0
Other acquisitions and investments	(190)	(353)
Acquisitions of property and equipment	(193)	(175)
Purchases of investment securities	(6)	(19)
Sales and maturities of investment securities	6	22
Other, net	(6)	26
Cash flows from investing activities	(9,588)	(499)
Cash flows from financing activities
Proceeds from Short-Term Debt	5,008	0
Repayments of other short-term borrowings	(5,005)	0
Proceeds from issuance of long-term debt	14,963
Repayments of long-term debt and finance lease obligations	(103)	(1,351)
Payments of Debt Issuance Costs	(99)	0
Dividends paid	(2,772)	(2,661)
Purchases of treasury stock	(1,324)	(1,955)
Proceeds from the exercise of stock options	127	65
Payments of contingent consideration liabilities	0	(311)
Other, net	24	21
Cash flows from financing activities	10,819	(6,192)
Effect of exchange rate changes on cash and equivalents	(18)	8
Net change in cash and equivalents	5,253	(2,490)
Cash and equivalents, beginning of period	12,814	9,201
Cash and equivalents, end of period	$ 18,067	$ 6,711

Basis of Presentation

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Basis of Historical Presentation The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2023. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain other reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation. On February 12, 2024, AbbVie completed its previously announced acquisition of ImmunoGen, Inc. (ImmunoGen). Refer to Note 4 and Note 8 for additional information regarding this acquisition. Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted ASU No. 2023-09 In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes - Improvements to Income Tax Disclosures (Topic 740) . The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard will be effective for AbbVie starting in annual periods in 2025, with early adoption permitted. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. ASU No. 2023-07 In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting - Improving Reportable Segment Disclosures (Topic 280) . The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (CODM), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The standard is effective for AbbVie starting in annual periods in 2024 and interim periods in 2025, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.

Supplemental Financial Informat

Supplemental Financial Information	3 Months Ended
Supplemental Financial Information	Mar. 31, 2024
Supplemental Financial Information
Supplemental Financial Information	Supplemental Financial Information Interest Expense, Net Three months ended (in millions) 2024 2023 Interest expense $ 660 $ 553 Interest income (207) (99) Interest expense, net $ 453 $ 454 Inventories (in millions) March 31, December 31, Finished goods $ 1,258 $ 1,356 Work-in-process 1,890 1,643 Raw materials 1,097 1,100 Inventories $ 4,245 $ 4,099 Property and Equipment, Net (in millions) March 31, December 31, Property and equipment, gross $ 11,725 $ 11,635 Accumulated depreciation (6,745) (6,646) Property and equipment, net $ 4,980 $ 4,989 Depreciation expense was $183 million for the three months ended March 31, 2024 and $179 million for the three months ended March 31, 2023.

Earnings Per Share

Earnings Per Share	3 Months Ended
Earnings Per Share	Mar. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method: Three months ended (in millions, except per share data) 2024 2023 Basic EPS Net earnings attributable to AbbVie Inc. $ 1,369 $ 239 Earnings allocated to participating securities 10 11 Earnings available to common shareholders $ 1,359 $ 228 Weighted-average basic shares outstanding 1,769 1,770 Basic earnings per share attributable to AbbVie Inc. $ 0.77 $ 0.13 Diluted EPS Net earnings attributable to AbbVie Inc. $ 1,369 $ 239 Earnings allocated to participating securities 10 11 Earnings available to common shareholders $ 1,359 $ 228 Weighted-average shares of common stock outstanding 1,769 1,770 Effect of dilutive securities 4 6 Weighted-average diluted shares outstanding 1,773 1,776 Diluted earnings per share attributable to AbbVie Inc. $ 0.77 $ 0.13 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Licensing, Acquisitions and Oth

Licensing, Acquisitions and Other Arrangements	3 Months Ended
Licensing, Acquisitions and Other Arrangements	Mar. 31, 2024
Licensing, Acquisitions, and Other Arrangements
Licensing, Acquisitions, and Other Arrangements	Licensing, Acquisitions and Other Arrangements Acquisition of ImmunoGen, Inc. On February 12, 2024, AbbVie completed its previously announced acquisition of ImmunoGen. ImmunoGen is a commercial-stage biotechnology company focused on the discovery, development and commercialization of antibody-drug conjugates (ADC) for cancer patients. ImmunoGen's oncology portfolio includes its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors. The combination accelerates AbbVie’s entry into the solid tumor space and strengthens its oncology pipeline. Under the terms of the agreement, AbbVie acquired all outstanding shares of ImmunoGen for $31.26 per share in cash. The total fair value of the consideration transferred to owners of ImmunoGen common stock was $9.8 billion ($9.2 billion, net of cash acquired). The acquisition of ImmunoGen has been accounted for as a business combination using the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The valuation of assets acquired and liabilities assumed has not yet been finalized as of March 31, 2024. As a result, AbbVie recorded preliminary estimates for the fair value of assets acquired and liabilities assumed as of the acquisition date. Finalization of the valuation during the measurement period could result in a change in the amounts recorded for the acquisition date fair value of intangible assets, goodwill and income taxes among other items. The completion of the valuation will occur no later than one year from the acquisition date. The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 591 Accounts receivable 171 Inventories 211 Prepaid expenses and other current assets 40 Property and equipment, net 7 Intangible assets, net Developed product rights 7,200 License agreements 125 Acquired in-process research and development 1,280 Other noncurrent assets 273 Current portion of long-term debt (99) Accounts payable and accrued liabilities (312) Deferred income taxes (899) Other long-term liabilities (47) Total identifiable net assets 8,541 Goodwill 1,249 Total assets acquired and liabilities assumed $ 9,790 The fair value step-up adjustment to inventories of $179 million is being amortized to cost of products sold when the inventory is sold to customers, which is expected to be within approximately one year from the acquisition date. Intangible assets relate to $7.3 billion of definite-lived intangible assets and $1.3 billion of acquired in-process research and development (IPR&D) associated with products that have not yet received regulatory approval. The acquired definite-lived intangible assets consist of developed product rights and license agreements and are being amortized over a weighted-average estimated useful life of approximately 12 years using the estimated pattern of economic benefit. The estimated fair values of identifiable intangible assets were determined using the "income approach" which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product, the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, competitive trends impacting the asset and each cash flow stream, as well as other factors. Other noncurrent assets primarily consist of $250 million of deferred tax assets. The current portion of long-term debt assumed by AbbVie was repaid concurrent with the acquisition at the fair value of $99 million. See Note 8 for additional information. Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recognized from the acquisition of ImmunoGen represents expected synergies including, the ability to: (i) expand AbbVie’s product portfolio as well as the potential to increase revenue from future growth platforms, (ii) accelerate AbbVie’s clinical and commercial presence in the solid tumor space within oncology, (iii) leverage the respective strengths of each company, and (iv) enhance AbbVie’s existing ADC development efforts. The goodwill is not deductible for tax purposes. Following the acquisition date, the operating results of ImmunoGen have been included in the condensed consolidated financial statements. For the period from the acquisition date through March 31, 2024, net revenues attributable to ImmunoGen were $91 million and operating losses attributable to ImmunoGen were $404 million, inclusive of $349 million of cash-settled, post-closing expense for ImmunoGen employee incentive awards, $47 million of inventory fair value step-up amortization and $21 million of intangible asset amortization. AbbVie also issued 0.3 million RSUs to holders of ImmunoGen equity awards based on a conversion factor described in the transaction agreement. Stock compensation expense related to the issued RSUs during the three months ended March 31, 2024 was not significant. Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $59 million for the three months ended March 31, 2024 and were included in selling, general and administrative (SG&A) expense in the condensed consolidated statements of earnings . Pro Forma Financial Information The following table presents the unaudited pro forma combined results of AbbVie and ImmunoGen for the three months ended March 31, 2024 and 2023 as if the acquisition of ImmunoGen had occurred on January 1, 2023: Three months ended March 31, (in millions) 2024 2023 Net revenues $ 12,365 $ 12,275 Net earnings (loss) 1,739 (413) The unaudited pro forma combined financial information was prepared using the acquisition method of accounting and was based on the historical financial information of AbbVie and ImmunoGen. In order to reflect the occurrence of the acquisition on January 1, 2023 as required, the unaudited pro forma financial information includes adjustments to reflect incremental amortization expense to be incurred based on the current preliminary fair values of the identifiable intangible assets acquired; the incremental cost of products sold related to the fair value adjustments associated with acquisition date inventory; the additional interest expense associated with the issuance of debt to finance the acquisition; and the reclassification of acquisition-related costs incurred during the three months ended March 31, 2024 to the three months ended March 31, 2023. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisition been completed on January 1, 2023. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. Proposed Acquisition of Cerevel Therapeutics Holdings, Inc. On December 6, 2023, AbbVie announced that it entered into a definitive agreement under which AbbVie will acquire Cerevel Therapeutics Holdings, Inc. (Cerevel Therapeutics). Under the terms of the agreement, AbbVie will acquire all outstanding shares of Cerevel Therapeutics for $45.00 per share in cash for a total value of approximately $8.7 billion. The transaction is expected to close in 2024 subject to regulatory approvals and other customary closing conditions. Cerevel Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of differentiated therapies for Neuroscience diseases. Cerevel Therapeutics neuroscience pipeline includes multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders. Other Licensing & Acquisitions Activity Cash outflows related to other acquisitions and investments totaled $190 million for the three months ended March 31, 2024 and $353 million for the three months ended March 31, 2023. The following table summarizes acquired IPR&D and milestones expense: Three months ended (in millions) 2024 2023 Upfront charges $ 79 $ 132 Development milestones 85 18 Acquired IPR&D and milestones $ 164 $ 150

Collaborations

Collaborations	3 Months Ended
Collaborations	Mar. 31, 2024
Collaborative Arrangements [Abstract]
Collaborations	Collaborations The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended March 31, 2024 and 2023. Collaboration with Janssen Biotech, Inc. In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton’s tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States. The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs. In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended (in millions) 2024 2023 United States - Janssen's share of profits (included in cost of products sold) $ 283 $ 297 International - AbbVie's share of profits (included in net revenues) 228 240 Global - AbbVie's share of other costs (included in respective line items) 42 55 AbbVie’s receivable from Janssen, included in accounts receivable, net, was $250 million at March 31, 2024 and $236 million at December 31, 2023. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $275 million at March 31, 2024 and $307 million at December 31, 2023. Collaboration with Genentech, Inc. AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie’s net revenues. Genentech’s share of United States profits is included in AbbVie’s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of SG&A expenses and global development costs as part of research and development (R&D) expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold. The following table shows the profit and cost sharing relationship between Genentech and AbbVie: Three months ended (in millions) 2024 2023 Genentech's share of profits, including royalties (included in cost of products sold) $ 227 $ 202 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 9 11 AbbVie's share of development costs (included in R&D) 19 28

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
Goodwill and Intangible Assets	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2023 $ 32,293 Additions (a) 1,249 Foreign currency translation adjustments (116) Balance as of March 31, 2024 $ 33,426 (a) Goodwill additions related to the acquisition of ImmunoGen (see Note 4). The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of March 31, 2024, there were no accumulated goodwill impairment losses. Intangible Assets, Net The following table summarizes intangible assets: March 31, 2024 December 31, 2023 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 82,219 $ (24,059) $ 58,160 $ 75,142 $ (22,455) $ 52,687 License agreements 8,316 (5,831) 2,485 8,191 (5,571) 2,620 Total definite-lived intangible assets 90,535 (29,890) 60,645 83,333 (28,026) 55,307 Indefinite-lived intangible assets 1,580 — 1,580 303 — 303 Total intangible assets, net $ 92,115 $ (29,890) $ 62,225 $ 83,636 $ (28,026) $ 55,610 Definite-Lived Intangible Assets The increase in definite-lived intangible assets during 2024 was primarily due to the acquisition of ImmunoGen. The intangible assets will be amortized using the estimated pattern of economic benefit. Refer to Note 4 for additional information regarding the acquisition. Amortization expense was $1.9 billion for the three months ended March 31, 2024 and 2023. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings. Indefinite-Lived Intangible Assets Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist. The increase in indefinite-lived intangible assets during 2024 was primarily due to the acquisition of ImmunoGen. Refer to Note 4 for additional information regarding the acquisition.

Restructuring Plans

Restructuring Plans	3 Months Ended
Restructuring Plans	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Integration and Restructuring Plans	Restructuring Plans AbbVie continuously evaluates its operations to identify opportunities to optimize its manufacturing and R&D operations, commercial infrastructure and administrative costs and to respond to changes in its business environment. As a result, AbbVie management periodically approves individual restructuring plans to achieve these objectives. As of March 31, 2024 and 2023, no such plans were individually significant. Restructuring charges were $15 million for the three months ended March 31, 2024 and $27 million for the three months ended March 31, 2023. These charges are recorded in cost of products sold, R&D expense and SG&A expense in the condensed consolidated statements of earnings based on the classification of the affected employees or the related operations. The following table summarizes the cash activity in the restructuring reserve for the three months ended March 31, 2024: (in millions) Accrued balance as of December 31, 2023 $ 196 Restructuring charges 14 Payments and other adjustments (32) Accrued balance as of March 31, 2024 $ 178 Allergan Integration Plan Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization and incurred total cumulative charges of $2.5 billion through December 31, 2023 . These costs consisted of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration ex penses. The Allergan integration plan was substantially complete as of December 31, 2023 and the remaining accrual as of March 31, 2024 is not significant. The following table summarizes the prior year charges associated with the Allergan acquisition integration plan: Three months ended (in millions) 2023 Cost of products sold $ 14 Research and development — Selling, general and administrative 44 Total charges $ 58

Financial Instruments and Fair

Financial Instruments and Fair Value Measures	3 Months Ended
Financial Instruments and Fair Value Measures	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measures	Financial Instruments and Fair Value Measures Risk Management Policy See Note 11 to the company’s Annual Report on Form 10-K for the year ended December 31, 2023 for a summary of AbbVie’s risk management policy and use of derivative instruments. Financial Instruments Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $1.1 billion at March 31, 2024 and $1.8 billion at December 31, 2023, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of March 31, 2024 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement. In 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in 2019 and the resulting net gain was recognized in AOCI. This gain is reclassified to interest expense, net over the term of the related debt. The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $6.2 billion at March 31, 2024 and $7.9 billion at December 31, 2023. The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had an aggregate principal amount of senior Euro notes designated as net investment hedges of €5.4 billion at March 31, 2024 and December 31, 2023. In addition, the company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling €4.9 billion, SEK1.4 billion, CAD750 million and CHF50 million at March 31, 2024 and December 31, 2023. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument. The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $5.0 billion at March 31, 2024 and December 31, 2023. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges. The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets: Fair value – Fair value – (in millions) Balance sheet caption March 31, 2024 December 31, 2023 Balance sheet caption March 31, 2024 December 31, 2023 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 30 $ 12 Accounts payable and accrued liabilities $ 4 $ 32 Designated as net investment hedges Prepaid expenses and other 53 13 Accounts payable and accrued liabilities 38 66 Designated as net investment hedges Other assets 6 — Other long-term liabilities 3 69 Not designated as hedges Prepaid expenses and other 10 41 Accounts payable and accrued liabilities 25 36 Interest rate swap contracts Designated as fair value hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 1 — Designated as fair value hedges Other assets — — Other long-term liabilities 357 293 Total derivatives $ 99 $ 66 $ 428 $ 496 While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets. The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss: Three months ended (in millions) 2024 2023 Foreign currency forward exchange contracts Designated as cash flow hedges $ 55 $ (9) Designated as net investment hedges 134 (94) Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $50 million into cost of products sold for foreign currency cash flow hedges and pre-tax gains of $23 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months. Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive loss pre-tax gains of $157 million for the three months ended March 31, 2024 and pre-tax losses of $162 million for the three months ended March 31, 2023. The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI. Three months ended (in millions) Statement of earnings caption 2024 2023 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 12 $ 30 Designated as net investment hedges Interest expense, net 27 28 Not designated as hedges Net foreign exchange loss (18) 30 Treasury rate lock agreements designated as cash flow hedges Interest expense, net 6 6 Interest rate swap contracts Designated as fair value hedges Interest expense, net (65) 35 Debt designated as hedged item in fair value hedges Interest expense, net 65 (35) Fair Value Measures The fair value hierarchy consists of the following three levels: • Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access; • Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and • Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability. The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of March 31, 2024: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 18,067 $ 7,221 $ 10,846 $ — Money market funds and time deposits 10 — 10 — Debt securities 26 — 26 — Equity securities 110 84 26 — Foreign currency contracts 99 — 99 — Total assets $ 18,312 $ 7,305 $ 11,007 $ — Liabilities Interest rate swap contracts $ 358 $ — $ 358 $ — Foreign currency contracts 70 — 70 — Contingent consideration 20,159 — — 20,159 Total liabilities $ 20,587 $ — $ 428 $ 20,159 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2023: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 12,814 $ 6,223 $ 6,591 $ — Money market funds and time deposits 10 — 10 — Debt securities 26 — 26 — Equity securities 111 86 25 — Foreign currency contracts 66 — 66 — Total assets $ 13,027 $ 6,309 $ 6,718 $ — Liabilities Interest rate swap contracts $ 293 $ — $ 293 $ — Foreign currency contracts 203 — 203 — Contingent consideration 19,890 — — 19,890 Total liabilities $ 20,386 $ — $ 496 $ 19,890 Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs: March 31, 2024 December 31, 2023 Range Weighted average (a) Range Weighted average (a) Discount rate 4.6% - 5.8% 4.8% 4.3%- 5.9% 4.5% Probability of payment for royalties by indication (b) 89% - 100% 99% 89% - 100% 99% Projected year of payments 2024 - 2034 2030 2024 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excluding approved indications, the estimated probability of payment was 89% at March 31, 2024 and December 31, 2023. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs: Three months ended (in millions) 2024 2023 Beginning balance $ 19,890 $ 16,384 Change in fair value recognized in net earnings 660 1,872 Payments (391) (325) Ending balance $ 20,159 $ 17,931 The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. Contingent consideration payments of amounts up to the initial acquisition date fair value are classified as cash outflows from financing activities and payments of amounts in excess of the initial acquisition date fair value are classified as cash outflows from operating activities in the condensed consolidated statements of cash flows. Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of March 31, 2024 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other Significant unobservable inputs Liabilities Short-term borrowings $ 3 $ 3 $ — $ 3 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 10,194 10,021 9,687 334 — Long-term debt and finance lease obligations, excluding fair value hedges 64,140 60,887 60,469 418 — Total liabilities $ 74,337 $ 70,911 $ 70,156 $ 755 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2023 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other Significant unobservable inputs Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 7,191 $ 7,069 $ 6,862 $ 207 $ — Long-term debt and finance lease obligations, excluding fair value hedges 52,460 49,541 48,983 558 — Total liabilities $ 59,651 $ 56,610 $ 55,845 $ 765 $ — AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $161 million as of March 31, 2024 and $159 million as of December 31, 2023. No significant cumulative upward or downward adjustments have been recorded for these investments as of March 31, 2024. Concentrations of Risk Of total net accounts receivable, three U.S. wholesalers accounted for 79% as of March 31, 2024 and 81% as of December 31, 2023, and substantially all of AbbVie’s pharmaceutical product net revenues in the United States were to these three wholesalers. Debt and Credit Facilities Financing Related to ImmunoGen and Cerevel Therapeutics Acquisitions In connection with the acquisition of ImmunoGen and proposed acquisition of Cerevel Therapeutics, in February, 2024, the company issued $15.0 billion aggregate principal amount of unsecured senior notes. The notes are unsecured, unsubordinated obligations of AbbVie and will rank equally in right of payment with all of AbbVie’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations. AbbVie may redeem the fixed-rate senior notes prior to maturity at a redemption price equal to the greater of the principal amount or the sum of present values of the remaining scheduled payments of principal and interest on the fixed-rate senior notes to be redeemed plus a make-whole premium. AbbVie may also redeem the fixed-rate senior notes at par between one and six months prior to maturity. In connection with the offering, debt issuance costs incurred totaled $99 million and debt discounts totaled $37 million, which are being amortized over the respective terms of the notes to interest expense, net in the condensed consolidated statements of earnings. AbbVie used the net proceeds received from the issuance of the notes to finance the acquisition of ImmunoGen, repay its term-loan, repay commercial paper borrowings, pay fees and expenses in respect of the foregoing, finance general corporate purposes and expects, together with cash on hand, to fund AbbVie’s proposed acquisition of Cerevel Therapeutics. See Note 4 for additional information. The following table summarizes issued debt in connection with the acquisition of ImmunoGen and proposed acquisition of Cerevel Therapeutics: (in millions) March 31, 2024 Senior Notes 4.80% Senior Notes due 2027 $ 2,250 4.80% Senior Notes due 2029 2,500 4.95% Senior Notes due 2031 2,000 5.05% Senior Notes due 2034 3,000 5.35% Senior Notes due 2044 750 5.40% Senior Notes due 2054 3,000 5.50% Senior Notes due 2064 1,500 Total acquired debt outstanding $ 15,000 In December 2023, AbbVie entered into a $9.0 billion 364-day bridge credit agreement and $5.0 billion 364-day term loan credit agreement. In February, 2024, AbbVie borrowed and repaid $5.0 billion under the term loan credit agreement. Interest charged on this borrowing was based on Secured Overnight Financing Rate Reference Rate (SOFR) +0.975% with an effective interest rate of 6.29%. Subsequent to the $15.0 billion issuance of senior notes, AbbVie terminated both the bridge and term loan credit agreements in the first quarter of 2024. In February 2024, concurrent with the acquisition, the company assumed and repaid an ImmunoGen senior secured term loan at a fair value of $99 million. Long-Term Debt Repayments In January 2023, the company repaid a $1.0 billion floating rate three-year term loan that was scheduled to mature in May 2023. In March 2023, the company repaid a $350 million aggregate principal amount of 2.80% senior notes at maturity. Short-Term Borrowings During the three months ended March 31, 2024, the company issued and redeemed $1.7 billion of commercial paper. There were no commercial paper borrowings outstanding as of March 31, 2024 and December 31, 2023. The weighted average interest rate on commercial paper borrowings was 5.54% for the three months ended March 31, 2024. In March 2023, AbbVie entered into an amended and restated five-year revolving credit facility. The amendment increased the unsecured revolving credit facility commitments from $4.0 billion to $5.0 billion and extended the maturity date of the facility from August 2023 to March 2028. This amended facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At March 31, 2024, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facilities as of March 31, 2024 and December 31, 2023.

Post-Employment Benefits

Post-Employment Benefits	3 Months Ended
Post-Employment Benefits	Mar. 31, 2024
Postemployment Benefits [Abstract]
Post-Employment Benefits	Post-Employment Benefits The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Three months ended (in millions) 2024 2023 2024 2023 Service cost $ 72 $ 68 $ 11 $ 8 Interest cost 113 107 10 9 Expected return on plan assets (197) (180) — — Amortization of prior service credit — — (9) (9) Amortization of actuarial loss 13 4 4 3 Net periodic benefit cost $ 1 $ (1) $ 16 $ 11 The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.

Equity

Equity	3 Months Ended
Equity	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Equity	Equity Stock-Based Compensation Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows: Three months ended (in millions) 2024 2023 Cost of products sold $ 22 $ 20 Research and development 133 117 Selling, general and administrative 193 176 Pre-tax compensation expense 348 313 Tax benefit 60 55 After-tax compensation expense $ 288 $ 258 In addition to stock-based compensation expense included in the table above and in connection with the acquisition of ImmunoGen, AbbVie incurred $349 million of cash-settled, post-closing expense for ImmunoGen employee incentive awards, of which $192 million was recorded in SG&A expenses, $126 million was recorded in R&D expenses and $31 million was recorded in cost of products sold in the condensed consolidated statements of earnings for the three months ended March 31, 2024. Refer to Note 4 for additional information regarding the ImmunoGen acquisition. Stock Options During the three months ended March 31, 2024, primarily in connection with the company's annual grant, AbbVie granted 0.6 million stock options with a weighted-average grant-date fair value of $31.53. As of March 31, 2024, $11 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years. RSUs and Performance Shares During the three months ended March 31, 2024, primarily in connection with the company's annual grant, AbbVie granted 4.9 million RSUs and performance shares with a weighted-average grant-date fair value of $175.97. In connection with the ImmunoGen acquisition, during the first quarter of 2024, AbbVie issued 0.3 million RSUs to holders of ImmunoGen equity awards based on a conversion factor described in the transaction agreement. Refer to Note 4 for additional information regarding the ImmunoGen acquisition. As of March 31, 2024, $967 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years. Cash Dividends The following table summarizes quarterly cash dividends declared during 2024 and 2023: 2024 2023 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 02/15/24 05/15/24 $ 1.55 10/26/23 02/15/24 $ 1.55 09/08/23 11/15/23 $ 1.48 06/22/23 08/15/23 $ 1.48 02/16/23 05/15/23 $ 1.48 Stock Repurchase Program The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes. On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 5 million shares for $959 million during the three months ended March 31, 2024 and 10 million shares for $1.6 billion during the three months ended March 31, 2023. AbbVie's remaining stock repurchase authorization was approximately $3.9 billion as of March 31, 2024. Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2024: (in millions) Foreign currency Net investment hedging activities Pension and post-employment Cash flow hedging Total Balance as of December 31, 2023 $ (1,106) $ 65 $ (1,488) $ 224 $ (2,305) Other comprehensive income (loss) before reclassifications (396) 228 3 44 (121) Net losses (gains) reclassified from accumulated other comprehensive loss — (21) 7 (14) (28) Net current-period other comprehensive income (loss) (396) 207 10 30 (149) Balance as of March 31, 2024 $ (1,502) $ 272 $ (1,478) $ 254 $ (2,454) Other comprehensive loss for the three months ended March 31, 2024 included foreign currency translation adjustments totaling a loss of $396 million principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling a gain of $207 million. The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2023: (in millions) Foreign currency Net investment hedging activities Pension Cash flow hedging Total Balance as of December 31, 2022 $ (1,513) $ 464 $ (1,458) $ 308 $ (2,199) Other comprehensive income (loss) before reclassifications 194 (202) 40 (10) 22 Net gains reclassified from accumulated other comprehensive loss — (22) (2) (31) (55) Net current-period other comprehensive income (loss) 194 (224) 38 (41) (33) Balance as of March 31, 2023 $ (1,319) $ 240 $ (1,420) $ 267 $ (2,232) Other comprehensive loss for the three months ended March 31, 2023 included foreign currency translation adjustments totaling a gain of $194 million principally due to the impact of the strengthening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling a loss of $224 million. The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: Three months ended (in millions) (brackets denote gains) 2024 2023 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (27) $ (28) Tax expense 6 6 Total reclassifications, net of tax $ (21) $ (22) Pension and post-employment benefits Amortization of actuarial losses (gains) and other (b) $ 8 $ (2) Tax benefit (1) — Total reclassifications, net of tax $ 7 $ (2) Cash flow hedging activities Gains on foreign currency forward exchange contracts (c) $ (12) $ (30) Gains on treasury rate lock agreements (a) (6) (6) Tax expense 4 5 Total reclassifications, net of tax $ (14) $ (31) (a) Amounts are included in interest expense, net (see Note 8). (b) Amounts are included in the computation of net periodic benefit cost (see Note 9). (c) Amounts are included in cost of products sold (see Note 8).

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rate was 22% for the three months ended March 31, 2024 compared to 49% for the three months ended March 31, 2023. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, changes in fair value of contingent consideration and business development activities, including ImmunoGen acquisition-related costs. The decrease in the effective tax rate for the three months ended March 31, 2024 over the prior year was primarily due to changes in fair value of contingent consideration and impairment of certain intangible assets in the prior year.

Legal Proceedings and Contingen

Legal Proceedings and Contingencies	3 Months Ended
Legal Proceedings and Contingencies	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows. Subject to certain exceptions specified in the separation agreement by and between Abbott Laboratories (Abbott) and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. Antitrust Litigation Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of six individual plaintiff lawsuits and a certified class action by Niaspan direct purchasers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation, MDL No. 2460. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. In November 2022, the State of Oregon filed a lawsuit in the Multnomah County, Oregon Circuit Court making similar allegations regarding the 2011 patent litigation with one of the generic companies. Lawsuits were filed against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with six generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, were consolidated as In re: Bystolic Antitrust Litigation in the United States District Court for the Southern District of New York. In February 2023, the court granted Forest Laboratories’ motion to dismiss the cases, dismissing them with prejudice. Plaintiffs are appealing the court’s motion to dismiss ruling. Government Proceedings Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 580 lawsuits are pending against Allergan in federal and state courts. Most of the federal court lawsuits are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately 130 of the lawsuits are pending in various state courts. The plaintiffs in these lawsuits, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. Of these approximately 580 lawsuits, approximately 165 of them are brought by states, counties, cities, and other municipal entities, approximately 125 of which are in the process of being dismissed pursuant to the previously announced settlement for which AbbVie recorded a charge of $2.1 billion to selling, general and administrative expense in the consolidated statement of earnings in the second quarter of 2022. In March 2023, AbbVie Inc. filed a petition in the United States Tax Court, AbbVie Inc. and Subsidiaries v. Commissioner of Internal Revenue. The petition disputes the Internal Revenue Service determination concerning a $572 million income tax benefit recorded in 2014 related to a payment made to a third party for the termination of a proposed business combination. Shareholder and Securities Litigation In October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class. Lawsuits were filed against Allergan and certain of its former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation. The plaintiffs generally seek compensatory damages and attorneys’ fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class. In December 2022, the court granted Allergan's motion for summary judgment on the remaining claims, dismissing them with prejudice. In February 2024, the United States Court of Appeals for the Second Circuit affirmed the district court’s dismissals. In May and July 2022, two shareholder derivative lawsuits, Treppel Family Trust v. Gonzalez et al., and Katcher v. Gonzalez, et al., were filed in the United States District Court for the Northern District of Illinois, alleging that certain AbbVie directors and officers breached fiduciary and other legal duties in making or allowing alleged misstatements regarding the potential effect that safety information about another company’s product would have on the Food and Drug Administration’s approval and labeling for AbbVie’s Rinvoq. Product Liability and General Litigation In April 2023, a putative class action lawsuit, Camargo v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois on behalf of Humira patients who paid for Humira based on its list price or who, after losing insurance coverage, discontinued Humira because they could not pay based on its list price, alleging that Humira’s list price is excessive in violation of multiple states’ unfair and deceptive trade practices statutes. The plaintiff generally seeks monetary damages, injunctive relief, and attorneys’ fees. In 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al., was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator sought damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit. In March 2023, the court granted Allergan’s motion to dismiss, dismissing plaintiff-relator’s federal law claims with prejudice and state law claims without prejudice. The plaintiff-relator is appealing the court’s motion to dismiss ruling. Intellectual Property Litigation AbbVie Inc. is seeking to enforce patent rights relating to venetoclax (a drug sold under the trademark Venclexta). Litigation was filed in the United States District Court for the District of Delaware in July 2020 against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc.; and Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., and Alembic Global Holdings SA. AbbVie alleges defendants’ proposed generic venetoclax products infringe certain patents and seeks declaratory and injunctive relief. Genentech, Inc., which is in a global collaboration with AbbVie concerning the development and marketing of Venclexta, is the co-plaintiff in this suit. AbbVie Inc. is seeking to enforce patent rights relating to upadacitinib (a drug sold under the trademark Rinvoq). Litigation was filed in the United States District Court for the District of Delaware in November 2023 against Hetero USA, Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd., Sandoz, Inc. Sandoz Private Limited, Sandoz GMBH, Intas Pharmaceuticals Ltd., Accord Healthcare, Inc., and Sun Pharmaceutical Industries, Ltd. AbbVie alleges defendants’ proposed generic upadacitinib products infringe certain patents and seeks declaratory and injunctive relief. AbbVie Inc. is seeking to enforce patent rights related to ubrogepant (a drug sold under the trademark Ubrelvy). Litigation was filed in the United States District Court for the District of New Jersey in March 2024 against Aurobindo Pharma U.S.A., Inc., Aurobindo Pharma Limited, and Apitoria Pharma Private Limited; Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited; MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited; and Hetero USA Inc., Hetero Labs Limited Unit-III, and Hetero Labs Limited. AbbVie alleges defendants’ proposed generic ubrogepant products infringe certain patents and seeks declaratory and injunctive relief. Merck Sharp & Dohme LLC, which exclusively licenses certain patents to AbbVie, is a co-plaintiff in the litigation.

Segment Information

Segment Information	3 Months Ended
Segment Information	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Information	Segment Information AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods. The following table details AbbVie’s worldwide net revenues: Three months ended (in millions) 2024 2023 Immunology Humira United States $ 1,771 $ 2,948 International 499 593 Total $ 2,270 $ 3,541 Skyrizi United States $ 1,656 $ 1,139 International 352 221 Total $ 2,008 $ 1,360 Rinvoq United States $ 725 $ 449 International 368 237 Total $ 1,093 $ 686 Oncology Imbruvica United States $ 610 $ 638 Collaboration revenues 228 240 Total $ 838 $ 878 Venclexta United States $ 281 $ 265 International 333 273 Total $ 614 $ 538 Elahere (a) United States $ 64 $ — Epkinly Collaboration Revenues $ 22 $ — International 5 — Total $ 27 $ — Aesthetics Botox Cosmetic United States $ 389 $ 409 International 244 250 Total $ 633 $ 659 Juvederm Collection United States $ 106 $ 122 International 191 233 Total $ 297 $ 355 Other Aesthetics United States $ 281 $ 246 International 38 40 Total $ 319 $ 286 Neuroscience Botox Therapeutic United States $ 611 $ 587 International 137 132 Total $ 748 $ 719 Vraylar United States $ 692 $ 560 International 2 1 Total $ 694 $ 561 Three months ended (in millions) 2024 2023 Duodopa United States $ 25 $ 25 International 90 93 Total $ 115 $ 118 Ubrelvy United States $ 197 $ 150 International 6 2 Total $ 203 $ 152 Qulipta United States $ 128 $ 66 International 3 — Total $ 131 $ 66 Other Neuroscience United States $ 61 $ 75 International 13 4 Total $ 74 $ 79 Eye Care Ozurdex United States $ 34 $ 39 International 97 76 Total 131 115 Lumigan/Ganfort United States $ 29 $ 63 International 62 67 Total $ 91 $ 130 Alphagan/Combigan United States $ 15 $ 28 International 44 43 Total $ 59 $ 71 Restasis United States $ 44 $ 79 International 13 13 Total $ 57 $ 92 Other Eye Care United States $ 105 $ 110 International 95 90 Total $ 200 $ 200 Other Key Products Mavyret United States $ 144 $ 171 International 205 193 Total $ 349 $ 364 Creon United States $ 285 $ 305 Linzess/Constella United States $ 257 $ 251 International 9 8 Total $ 266 $ 259 All other $ 744 $ 691 Total net revenues $ 12,310 $ 12,225 (a) Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	3 Months Ended
Supplemental Financial Information (Tables)	Mar. 31, 2024
Supplemental Financial Information
Schedule of interest expense, net	Interest Expense, Net Three months ended (in millions) 2024 2023 Interest expense $ 660 $ 553 Interest income (207) (99) Interest expense, net $ 453 $ 454
Schedule of inventories	Inventories (in millions) March 31, December 31, Finished goods $ 1,258 $ 1,356 Work-in-process 1,890 1,643 Raw materials 1,097 1,100 Inventories $ 4,245 $ 4,099
Schedule of property and equipment, net	Property and Equipment, Net (in millions) March 31, December 31, Property and equipment, gross $ 11,725 $ 11,635 Accumulated depreciation (6,745) (6,646) Property and equipment, net $ 4,980 $ 4,989

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
Earnings Per Share (Tables)	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per share, impact of two-class method	The following table summarizes the impact of the two-class method: Three months ended (in millions, except per share data) 2024 2023 Basic EPS Net earnings attributable to AbbVie Inc. $ 1,369 $ 239 Earnings allocated to participating securities 10 11 Earnings available to common shareholders $ 1,359 $ 228 Weighted-average basic shares outstanding 1,769 1,770 Basic earnings per share attributable to AbbVie Inc. $ 0.77 $ 0.13 Diluted EPS Net earnings attributable to AbbVie Inc. $ 1,369 $ 239 Earnings allocated to participating securities 10 11 Earnings available to common shareholders $ 1,359 $ 228 Weighted-average shares of common stock outstanding 1,769 1,770 Effect of dilutive securities 4 6 Weighted-average diluted shares outstanding 1,773 1,776 Diluted earnings per share attributable to AbbVie Inc. $ 0.77 $ 0.13

Licensing, Acquisitions and O_2

Licensing, Acquisitions and Other Arrangements (Tables)		3 Months Ended
Licensing, Acquisitions and Other Arrangements (Tables)	Feb. 12, 2024	Mar. 31, 2024
Licensing, Acquisitions, and Other Arrangements
Schedule of fair value of assets acquired and liabilities assumed	The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 591 Accounts receivable 171 Inventories 211 Prepaid expenses and other current assets 40 Property and equipment, net 7 Intangible assets, net Developed product rights 7,200 License agreements 125 Acquired in-process research and development 1,280 Other noncurrent assets 273 Current portion of long-term debt (99) Accounts payable and accrued liabilities (312) Deferred income taxes (899) Other long-term liabilities (47) Total identifiable net assets 8,541 Goodwill 1,249 Total assets acquired and liabilities assumed $ 9,790
Schedule of unaudited pro forma combined results	The following table presents the unaudited pro forma combined results of AbbVie and ImmunoGen for the three months ended March 31, 2024 and 2023 as if the acquisition of ImmunoGen had occurred on January 1, 2023: Three months ended March 31, (in millions) 2024 2023 Net revenues $ 12,365 $ 12,275 Net earnings (loss) 1,739 (413)
Schedule of Research and Development Assets Acquired Other than Through Business Combination		The following table summarizes acquired IPR&D and milestones expense: Three months ended (in millions) 2024 2023 Upfront charges $ 79 $ 132 Development milestones 85 18 Acquired IPR&D and milestones $ 164 $ 150

Collaborations (Tables)

Collaborations (Tables)	3 Months Ended
Collaborations (Tables)	Mar. 31, 2024
Janssen Biotech Inc.
Collaborative and license agreements
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended (in millions) 2024 2023 United States - Janssen's share of profits (included in cost of products sold) $ 283 $ 297 International - AbbVie's share of profits (included in net revenues) 228 240 Global - AbbVie's share of other costs (included in respective line items) 42 55
Genentech, Inc.
Collaborative and license agreements
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Genentech and AbbVie: Three months ended (in millions) 2024 2023 Genentech's share of profits, including royalties (included in cost of products sold) $ 227 $ 202 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 9 11 AbbVie's share of development costs (included in R&D) 19 28

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
Goodwill and Intangible Assets (Tables)	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of changes in the carrying amount of goodwill	The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2023 $ 32,293 Additions (a) 1,249 Foreign currency translation adjustments (116) Balance as of March 31, 2024 $ 33,426
Summary of definite-lived intangible assets	The following table summarizes intangible assets: March 31, 2024 December 31, 2023 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 82,219 $ (24,059) $ 58,160 $ 75,142 $ (22,455) $ 52,687 License agreements 8,316 (5,831) 2,485 8,191 (5,571) 2,620 Total definite-lived intangible assets 90,535 (29,890) 60,645 83,333 (28,026) 55,307 Indefinite-lived intangible assets 1,580 — 1,580 303 — 303 Total intangible assets, net $ 92,115 $ (29,890) $ 62,225 $ 83,636 $ (28,026) $ 55,610
Summary of indefinite-lived intangible assets	The following table summarizes intangible assets: March 31, 2024 December 31, 2023 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 82,219 $ (24,059) $ 58,160 $ 75,142 $ (22,455) $ 52,687 License agreements 8,316 (5,831) 2,485 8,191 (5,571) 2,620 Total definite-lived intangible assets 90,535 (29,890) 60,645 83,333 (28,026) 55,307 Indefinite-lived intangible assets 1,580 — 1,580 303 — 303 Total intangible assets, net $ 92,115 $ (29,890) $ 62,225 $ 83,636 $ (28,026) $ 55,610

Restructuring Plans (Tables)

Restructuring Plans (Tables)	3 Months Ended
Restructuring Plans (Tables)	Mar. 31, 2024	Mar. 31, 2023
Allergan integration plan
Restructuring charges
Summary of charges associated with integration plan		The following table summarizes the prior year charges associated with the Allergan acquisition integration plan: Three months ended (in millions) 2023 Cost of products sold $ 14 Research and development — Selling, general and administrative 44 Total charges $ 58
Other restructuring
Restructuring charges
Summary of cash activity in the restructuring reserve	The following table summarizes the cash activity in the restructuring reserve for the three months ended March 31, 2024: (in millions) Accrued balance as of December 31, 2023 $ 196 Restructuring charges 14 Payments and other adjustments (32) Accrued balance as of March 31, 2024 $ 178

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measures (Tables)	3 Months Ended
Financial Instruments and Fair Value Measures (Tables)	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summary of amounts and location of derivatives on the condensed consolidated balance sheets	The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets: Fair value – Fair value – (in millions) Balance sheet caption March 31, 2024 December 31, 2023 Balance sheet caption March 31, 2024 December 31, 2023 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 30 $ 12 Accounts payable and accrued liabilities $ 4 $ 32 Designated as net investment hedges Prepaid expenses and other 53 13 Accounts payable and accrued liabilities 38 66 Designated as net investment hedges Other assets 6 — Other long-term liabilities 3 69 Not designated as hedges Prepaid expenses and other 10 41 Accounts payable and accrued liabilities 25 36 Interest rate swap contracts Designated as fair value hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 1 — Designated as fair value hedges Other assets — — Other long-term liabilities 357 293 Total derivatives $ 99 $ 66 $ 428 $ 496
Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss: Three months ended (in millions) 2024 2023 Foreign currency forward exchange contracts Designated as cash flow hedges $ 55 $ (9) Designated as net investment hedges 134 (94)
Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss: Three months ended (in millions) 2024 2023 Foreign currency forward exchange contracts Designated as cash flow hedges $ 55 $ (9) Designated as net investment hedges 134 (94)
Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings	The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI. Three months ended (in millions) Statement of earnings caption 2024 2023 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 12 $ 30 Designated as net investment hedges Interest expense, net 27 28 Not designated as hedges Net foreign exchange loss (18) 30 Treasury rate lock agreements designated as cash flow hedges Interest expense, net 6 6 Interest rate swap contracts Designated as fair value hedges Interest expense, net (65) 35 Debt designated as hedged item in fair value hedges Interest expense, net 65 (35)
Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis	The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of March 31, 2024: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 18,067 $ 7,221 $ 10,846 $ — Money market funds and time deposits 10 — 10 — Debt securities 26 — 26 — Equity securities 110 84 26 — Foreign currency contracts 99 — 99 — Total assets $ 18,312 $ 7,305 $ 11,007 $ — Liabilities Interest rate swap contracts $ 358 $ — $ 358 $ — Foreign currency contracts 70 — 70 — Contingent consideration 20,159 — — 20,159 Total liabilities $ 20,587 $ — $ 428 $ 20,159 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2023: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 12,814 $ 6,223 $ 6,591 $ — Money market funds and time deposits 10 — 10 — Debt securities 26 — 26 — Equity securities 111 86 25 — Foreign currency contracts 66 — 66 — Total assets $ 13,027 $ 6,309 $ 6,718 $ — Liabilities Interest rate swap contracts $ 293 $ — $ 293 $ — Foreign currency contracts 203 — 203 — Contingent consideration 19,890 — — 19,890 Total liabilities $ 20,386 $ — $ 496 $ 19,890
Summary of significant level 3 unobservable inputs	The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs: March 31, 2024 December 31, 2023 Range Weighted average (a) Range Weighted average (a) Discount rate 4.6% - 5.8% 4.8% 4.3%- 5.9% 4.5% Probability of payment for royalties by indication (b) 89% - 100% 99% 89% - 100% 99% Projected year of payments 2024 - 2034 2030 2024 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excluding approved indications, the estimated probability of payment was 89% at March 31, 2024 and December 31, 2023.
Schedule of changes in fair value of Level 3 inputs	The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs: Three months ended (in millions) 2024 2023 Beginning balance $ 19,890 $ 16,384 Change in fair value recognized in net earnings 660 1,872 Payments (391) (325) Ending balance $ 20,159 $ 17,931
Schedule of book values, approximate fair values and bases used to measure certain financial instruments	The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of March 31, 2024 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other Significant unobservable inputs Liabilities Short-term borrowings $ 3 $ 3 $ — $ 3 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 10,194 10,021 9,687 334 — Long-term debt and finance lease obligations, excluding fair value hedges 64,140 60,887 60,469 418 — Total liabilities $ 74,337 $ 70,911 $ 70,156 $ 755 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2023 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other Significant unobservable inputs Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 7,191 $ 7,069 $ 6,862 $ 207 $ — Long-term debt and finance lease obligations, excluding fair value hedges 52,460 49,541 48,983 558 — Total liabilities $ 59,651 $ 56,610 $ 55,845 $ 765 $ —
Schedule of Long-Term Debt Instruments	The following table summarizes issued debt in connection with the acquisition of ImmunoGen and proposed acquisition of Cerevel Therapeutics: (in millions) March 31, 2024 Senior Notes 4.80% Senior Notes due 2027 $ 2,250 4.80% Senior Notes due 2029 2,500 4.95% Senior Notes due 2031 2,000 5.05% Senior Notes due 2034 3,000 5.35% Senior Notes due 2044 750 5.40% Senior Notes due 2054 3,000 5.50% Senior Notes due 2064 1,500 Total acquired debt outstanding $ 15,000

Post-Employment Benefits (Table

Post-Employment Benefits (Tables)	3 Months Ended
Post-Employment Benefits (Tables)	Mar. 31, 2024
Postemployment Benefits [Abstract]
Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans	The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Three months ended (in millions) 2024 2023 2024 2023 Service cost $ 72 $ 68 $ 11 $ 8 Interest cost 113 107 10 9 Expected return on plan assets (197) (180) — — Amortization of prior service credit — — (9) (9) Amortization of actuarial loss 13 4 4 3 Net periodic benefit cost $ 1 $ (1) $ 16 $ 11

Equity (Tables)

Equity (Tables)	3 Months Ended
Equity (Tables)	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Summary of share-based compensation expense	Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows: Three months ended (in millions) 2024 2023 Cost of products sold $ 22 $ 20 Research and development 133 117 Selling, general and administrative 193 176 Pre-tax compensation expense 348 313 Tax benefit 60 55 After-tax compensation expense $ 288 $ 258
Summary of quarterly cash dividends	The following table summarizes quarterly cash dividends declared during 2024 and 2023: 2024 2023 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 02/15/24 05/15/24 $ 1.55 10/26/23 02/15/24 $ 1.55 09/08/23 11/15/23 $ 1.48 06/22/23 08/15/23 $ 1.48 02/16/23 05/15/23 $ 1.48
Summary of changes in balances of each component of accumulated other comprehensive loss	The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2024: (in millions) Foreign currency Net investment hedging activities Pension and post-employment Cash flow hedging Total Balance as of December 31, 2023 $ (1,106) $ 65 $ (1,488) $ 224 $ (2,305) Other comprehensive income (loss) before reclassifications (396) 228 3 44 (121) Net losses (gains) reclassified from accumulated other comprehensive loss — (21) 7 (14) (28) Net current-period other comprehensive income (loss) (396) 207 10 30 (149) Balance as of March 31, 2024 $ (1,502) $ 272 $ (1,478) $ 254 $ (2,454) The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2023: (in millions) Foreign currency Net investment hedging activities Pension Cash flow hedging Total Balance as of December 31, 2022 $ (1,513) $ 464 $ (1,458) $ 308 $ (2,199) Other comprehensive income (loss) before reclassifications 194 (202) 40 (10) 22 Net gains reclassified from accumulated other comprehensive loss — (22) (2) (31) (55) Net current-period other comprehensive income (loss) 194 (224) 38 (41) (33) Balance as of March 31, 2023 $ (1,319) $ 240 $ (1,420) $ 267 $ (2,232)
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss	The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: Three months ended (in millions) (brackets denote gains) 2024 2023 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (27) $ (28) Tax expense 6 6 Total reclassifications, net of tax $ (21) $ (22) Pension and post-employment benefits Amortization of actuarial losses (gains) and other (b) $ 8 $ (2) Tax benefit (1) — Total reclassifications, net of tax $ 7 $ (2) Cash flow hedging activities Gains on foreign currency forward exchange contracts (c) $ (12) $ (30) Gains on treasury rate lock agreements (a) (6) (6) Tax expense 4 5 Total reclassifications, net of tax $ (14) $ (31) (a) Amounts are included in interest expense, net (see Note 8). (b) Amounts are included in the computation of net periodic benefit cost (see Note 9). (c) Amounts are included in cost of products sold (see Note 8).

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
Segment Information (Tables)	Mar. 31, 2024
Segment Reporting [Abstract]
Schedule of worldwide net revenues	The following table details AbbVie’s worldwide net revenues: Three months ended (in millions) 2024 2023 Immunology Humira United States $ 1,771 $ 2,948 International 499 593 Total $ 2,270 $ 3,541 Skyrizi United States $ 1,656 $ 1,139 International 352 221 Total $ 2,008 $ 1,360 Rinvoq United States $ 725 $ 449 International 368 237 Total $ 1,093 $ 686 Oncology Imbruvica United States $ 610 $ 638 Collaboration revenues 228 240 Total $ 838 $ 878 Venclexta United States $ 281 $ 265 International 333 273 Total $ 614 $ 538 Elahere (a) United States $ 64 $ — Epkinly Collaboration Revenues $ 22 $ — International 5 — Total $ 27 $ — Aesthetics Botox Cosmetic United States $ 389 $ 409 International 244 250 Total $ 633 $ 659 Juvederm Collection United States $ 106 $ 122 International 191 233 Total $ 297 $ 355 Other Aesthetics United States $ 281 $ 246 International 38 40 Total $ 319 $ 286 Neuroscience Botox Therapeutic United States $ 611 $ 587 International 137 132 Total $ 748 $ 719 Vraylar United States $ 692 $ 560 International 2 1 Total $ 694 $ 561 Three months ended (in millions) 2024 2023 Duodopa United States $ 25 $ 25 International 90 93 Total $ 115 $ 118 Ubrelvy United States $ 197 $ 150 International 6 2 Total $ 203 $ 152 Qulipta United States $ 128 $ 66 International 3 — Total $ 131 $ 66 Other Neuroscience United States $ 61 $ 75 International 13 4 Total $ 74 $ 79 Eye Care Ozurdex United States $ 34 $ 39 International 97 76 Total 131 115 Lumigan/Ganfort United States $ 29 $ 63 International 62 67 Total $ 91 $ 130 Alphagan/Combigan United States $ 15 $ 28 International 44 43 Total $ 59 $ 71 Restasis United States $ 44 $ 79 International 13 13 Total $ 57 $ 92 Other Eye Care United States $ 105 $ 110 International 95 90 Total $ 200 $ 200 Other Key Products Mavyret United States $ 144 $ 171 International 205 193 Total $ 349 $ 364 Creon United States $ 285 $ 305 Linzess/Constella United States $ 257 $ 251 International 9 8 Total $ 266 $ 259 All other $ 744 $ 691 Total net revenues $ 12,310 $ 12,225 (a) Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.

Supplemental Financial Inform_3

Supplemental Financial Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Interest Expense, Net
Interest expense	$ 660	$ 553
Interest income	(207)	(99)
Interest expense, net	453	454
Inventories
Finished goods	1,258		$ 1,356
Work-in-process	1,890		1,643
Raw materials	1,097		1,100
Inventories	4,245		4,099
Property and Equipment
Property and equipment, gross	11,725		11,635
Accumulated depreciation	(6,745)		(6,646)
Property and equipment, net	4,980		$ 4,989
Depreciation expense	$ 183	$ 179

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Basic EPS
Net earnings attributable to AbbVie Inc.	$ 1,369	$ 239
Earnings allocated to participating securities	10	11
Earnings available to common shareholders	$ 1,359	$ 228
Weighted-average basic shares outstanding (in shares)	1,769	1,770
Basic earnings per share (in dollars per share)	$ 0.77	$ 0.13
Diluted EPS
Net earnings attributable to AbbVie Inc.	$ 1,369	$ 239
Earnings allocated to participating securities	10	11
Earnings available to common shareholders	$ 1,359	$ 228
Weighted-average basic shares outstanding (in shares)	1,769	1,770
Effect of dilutive securities (in shares)	4	6
Weighted-average diluted shares outstanding (in shares)	1,773	1,776
Diluted earnings per share (in dollars per share)	$ 0.77	$ 0.13

Licensing, Acquisitions and O_3

Licensing, Acquisitions and Other Arrangements - Acquisition of ImmunoGen (Details) - USD ($) $ / shares in Units, $ in Millions		2 Months Ended	3 Months Ended
	Feb. 12, 2024	Mar. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Business Acquisition
Amortization of intangible assets			$ 1,891	$ 1,948
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Goodwill		$ 33,426	33,426		$ 32,293
Pro Forma Information
Payments to Acquire Businesses, Net of Cash Acquired			9,199	0
ImmunoGen
Business Acquisition
Fair value step-up adjustment to inventories	$ 179
Weighted average useful life of acquired intangible assets		12 years
Net revenues attributable to ImmunoGen from acquisition date		$ 91
Operating earnings attributable to ImmunoGen from acquisition date		(404)
Inventory fair value step-up amortization		47
Amortization of intangible assets		21
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Cash and equivalents	591
Accounts receivable	171
Inventories	211
Prepaid expenses and other current assets	40
Property and equipment, net	7
Intangible Assets - Developed product rights	7,200
Business Combination Recognized Identifiable Assets Acquired And Liabilities License Agreements	125
Intangible assets - In-process research and development	1,280
Other noncurrent assets	273
Accounts payable and accrued liabilities	(312)
Current portion of long-term debt	(99)
Deferred income taxes	(899)
Other long-term liabilities	(47)
Total identifiable net assets	8,541
Goodwill	1,249
Total assets acquired and liabilities assumed	9,790
Pro Forma Information
Net revenues			12,365	12,275
Net earnings (loss)			$ 1,739	$ (413)
Cash consideration paid to ImmunoGen shareholders	9,800
Payments to Acquire Businesses, Net of Cash Acquired	9,200
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets	250
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized	349
Intangible Assets - Developed product rights	7,300
Intangible assets - In-process research and development	$ 1,300
Cash per share received by Cerevel Therapeutics shareholders (in dollars per share)	$ 31.26
ImmunoGen \| Selling, general and administrative
Business Acquisition
Acquisition-related expenses		$ 59

Licensing, Acquisitions and O_4

Licensing, Acquisitions and Other Arrangements (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Dec. 06, 2023	Mar. 31, 2024	Mar. 31, 2023
Collaborative and license agreements
Cash outflows related to acquisitions and investments		$ (190)	$ (353)
Acquired IPR&D and milestones		164	150
Cerevel Therapeutics
Collaborative and license agreements
Cash per share received by Cerevel Therapeutics shareholders (in dollars per share)	$ 45
Total consideration	$ 8,700
Collaborative arrangement
Collaborative and license agreements
Research and development milestone expenses		85	18
Other Collaboration Arrangements \| Collaborative arrangement
Collaborative and license agreements
Acquired IPR&D and milestones		$ 79	$ 132

Collaborations (Details)

Collaborations (Details) - USD ($) $ in Millions	3 Months Ended
Collaborations (Details) - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Collaborative and license agreements
AbbVie's receivable from Janssen	$ 11,949		$ 11,155
AbbVie's payable to Janssen	31,326		30,650
Janssen Biotech Inc. \| Collaborative arrangement
Collaborative and license agreements
Milestone payments	$ 200
Share of collaboration development costs responsible by Janssen (as a percent)	60%
Share of collaboration development costs responsible by the entity (as a percent)	40%
Global - AbbVie's share of other costs (included in respective line items)	$ 42	$ 55
AbbVie's receivable from Janssen	250		236
AbbVie's payable to Janssen	275		$ 307
Janssen Biotech Inc. \| Collaborative arrangement \| United States
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	283	297
Janssen Biotech Inc. \| Collaborative arrangement \| International
Collaborative and license agreements
International - AbbVie's share of profits (included in net revenues)	228	240
Genentech, Inc. \| Collaborative arrangement
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	227	202
AbbVie's share of development costs (included in R&D)	19	28
Genentech, Inc. \| Collaborative arrangement \| United States
Collaborative and license agreements
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	$ 9	$ 11

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details)	3 Months Ended
Goodwill and Intangible Assets - Goodwill (Details)	Mar. 31, 2024 USD ($)
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 32,293,000,000
Additions	1,249,000,000
Foreign currency translation adjustments	(116,000,000)
Balance at the end of the period	33,426,000,000
Accumulated goodwill impairment losses
Accumulated goodwill impairment losses	$ 0

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Finite-Lived Intangible Assets
Gross carrying amount	$ 90,535		$ 83,333
Accumulated amortization	(29,890)		(28,026)
Net carrying amount	60,645		55,307
Indefinite-lived intangible assets	1,580		303
Total intangible assets gross carrying amount	92,115		83,636
Intangible assets, net	62,225		55,610
Amortization expense	1,891	$ 1,948
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	0	710
AGN-151607 \| Research and development
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible assets		$ 630
Developed product rights
Finite-Lived Intangible Assets
Gross carrying amount	82,219		75,142
Accumulated amortization	(24,059)		(22,455)
Net carrying amount	58,160		52,687
License agreements
Finite-Lived Intangible Assets
Gross carrying amount	8,316		8,191
Accumulated amortization	(5,831)		(5,571)
Net carrying amount	$ 2,485		$ 2,620

Restructuring Plans (Details)

Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended
Restructuring Plans (Details) - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Allergan integration plan
Restructuring charges
Incurred total cumulative integration charges			$ 2,500
Charges associated with integration or restructuring plans		$ 58
Allergan integration plan \| Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans		14
Allergan integration plan \| Research and development
Restructuring charges
Charges associated with integration or restructuring plans		0
Allergan integration plan \| Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans		44
Other restructuring
Restructuring charges
Charges associated with integration or restructuring plans	$ 15	$ 27
Restructuring reserve rollforward
Accrued balance beginning of the period	196
Restructuring charges	14
Payments and other adjustments	(32)
Accrued balance end of the period	$ 178

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measures - Financial Instruments (Details) SFr in Millions, $ in Millions, € in Billions, kr in Billions

3 Months Ended

Mar. 31, 2024 USD ($)

Mar. 31, 2023 USD ($)

Mar. 31, 2024 EUR (€)

Mar. 31, 2024 SEK (kr)

Mar. 31, 2024 CAD ($)

Mar. 31, 2024 CHF (SFr)

Dec. 31, 2023 USD ($)

Dec. 31, 2023 EUR (€)

Dec. 31, 2023 SEK (kr)

Dec. 31, 2023 CAD ($)

Dec. 31, 2023 CHF (SFr)

Dec. 31, 2019 USD ($)

Derivative instruments, notional amount and fair value

Amount excluded from the assessment of effectiveness for cash flow hedges

$ 0

Amount excluded from the assessment of effectiveness for fair value hedges

$ 0

Fair value - Derivatives in asset position

99,000,000

$ 66,000,000

Fair value - Derivatives in liability position

428,000,000

496,000,000

Designated as hedging instrument | Net investment hedges | Senior notes

Derivative instruments, notional amount and fair value

Principal amount of unsecured senior notes | €

€ 5.4

Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

$ 1,100,000,000

1,800,000,000

Duration of forward exchange contracts

18 months

Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold

6 months

Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Prepaid expenses and other

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

$ 30,000,000

12,000,000

Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Accounts payable and accrued liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

4,000,000

32,000,000

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

€ 4.9

kr 1.4

$ 750

SFr 50

€ 4.9

kr 1.4

$ 750

SFr 50

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Prepaid expenses and other

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

53,000,000

13,000,000

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Accounts payable and accrued liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

38,000,000

66,000,000

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other assets

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

6,000,000

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other long-term liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

3,000,000

69,000,000

Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

$ 10,000,000,000

Designated as hedging instrument | Interest rate swap contracts | Fair value hedges

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

5,000,000,000

Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Prepaid expenses and other

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Accounts payable and accrued liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

1,000,000

Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other assets

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other long-term liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

357,000,000

293,000,000

Not designated as hedging instrument | Foreign currency forward exchange contracts

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

6,200,000,000

7,900,000,000

Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses and other

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

10,000,000

41,000,000

Not designated as hedging instrument | Foreign currency forward exchange contracts | Accounts payable and accrued liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

$ 25,000,000

$ 36,000,000

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cost of products sold
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months	$ 50
Interest expense, net
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months	23
Interest expense, net \| Fair value hedges
Gain (loss) on derivatives
Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings	65	$ (35)
Designated as hedging instrument \| Senior notes
Gain (loss) on derivatives
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	157	(162)
Foreign currency forward exchange contracts \| Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	55	(9)
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	134	(94)
Foreign currency forward exchange contracts \| Designated as hedging instrument \| Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 12	$ 30
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of products sold	Cost of products sold
Foreign currency forward exchange contracts \| Designated as hedging instrument \| Net investment hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 27	$ 28
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net
Foreign currency forward exchange contracts \| Not designated as hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ (18)	$ 30
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain (Loss), Foreign Currency Transaction, before Tax	Gain (Loss), Foreign Currency Transaction, before Tax
Interest rate swap contracts \| Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income		$ (31)
Interest rate swap contracts \| Designated as hedging instrument \| Fair value hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ (65)	$ 35
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net
Treasury rate lock agreements \| Designated as hedging instrument \| Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 6	$ 6
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Assets
Investment, Type [Extensible Enumeration]	Money Market Funds [Member]	Money Market Funds [Member]
Foreign currency contracts	$ 99	$ 66
Liabilities
Foreign currency contracts	428	496
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Total liabilities	70,156	55,845
Fair Value, Recurring
Assets
Cash and equivalents	18,067	12,814
Money market funds and time deposits	10	10
Debt securities	26	26
Equity securities	110	111
Total assets	18,312	13,027
Liabilities
Interest rate swap contracts	358	293
Contingent consideration	20,159	19,890
Total liabilities	20,587	20,386
Fair Value, Recurring \| Foreign currency contracts
Assets
Foreign currency contracts	99	66
Liabilities
Foreign currency contracts	70	203
Fair Value, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	7,221	6,223
Money market funds and time deposits	0	0
Debt securities	0	0
Equity securities	84	86
Total assets	7,305	6,309
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Fair Value, Recurring \| Significant other observable inputs (Level 2)
Assets
Cash and equivalents	10,846	6,591
Money market funds and time deposits	10	10
Debt securities	26	26
Equity securities	26	25
Total assets	11,007	6,718
Liabilities
Interest rate swap contracts	358	293
Contingent consideration	0	0
Total liabilities	428	496
Fair Value, Recurring \| Significant other observable inputs (Level 2) \| Foreign currency contracts
Assets
Foreign currency contracts	99	66
Liabilities
Foreign currency contracts	70	203
Fair Value, Recurring \| Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	0	0
Money market funds and time deposits	0	0
Debt securities	0	0
Equity securities	0	0
Total assets	0	0
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	20,159	19,890
Total liabilities	20,159	19,890
Fair Value, Recurring \| Significant unobservable inputs (Level 3) \| Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	$ 0	$ 0

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)		Mar. 31, 2024	Dec. 31, 2023
Weighted average \| Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[1]	0.048	0.045
Weighted average \| Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[1],[2]	0.99	0.99
Weighted average \| Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[1]	2,030	2,027
Minimum \| Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		0.046	0.043
Minimum \| Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[2]	0.89	0.89
Minimum \| Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		2,024	2,024
Minimum \| Probability of payment for royalties excluding approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		0.89
Maximum \| Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		0.058	0.059
Maximum \| Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[2]	1	1
Maximum \| Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		2,034	2,034
Maximum \| Probability of payment for royalties excluding approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		0.89

[1] (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excluding approved indications, the estimated probability of payment was 89% at March 31, 2024 and December 31, 2023.

Financial Instruments and Fai_7

Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Transfers of assets or liabilities between the fair value measurement levels
Transfers of assets into Level 3 of the fair value hierarchy	$ 0
Transfers of assets out of Level 3 of the fair value hierarchy	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]
Transfers of liabilities into Level 3 of the fair value hierarchy	0
Transfers of liabilities out of Level 3 of the fair value hierarchy	0
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Beginning balance	19,890,000,000	$ 16,384,000,000
Change in fair value recognized in net earnings	660,000,000	1,872,000,000
Payments	(391,000,000)	(325,000,000)
Ending balance	$ 20,159,000,000	$ 17,931,000,000

Financial Instruments and Fai_8

Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Liabilities
Carrying amount of investments in equity securities that do not have readily determinable fair values	$ 161	$ 159
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	9,687	6,862
Long-term debt and finance lease obligations, excluding fair value hedges	60,469	48,983
Total liabilities	70,156	55,845
Book value
Liabilities
Short-term borrowings	3
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	10,194	7,191
Long-term debt and finance lease obligations, excluding fair value hedges	64,140	52,460
Total liabilities	74,337	59,651
Approximate fair value
Liabilities
Short-term borrowings	3
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	10,021	7,069
Long-term debt and finance lease obligations, excluding fair value hedges	60,887	49,541
Total liabilities	70,911	56,610
Approximate fair value \| Quoted prices in active markets for identical assets (Level 1)
Liabilities
Short-term borrowings	0
Approximate fair value \| Significant other observable inputs (Level 2)
Liabilities
Short-term borrowings	3
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	334	207
Long-term debt and finance lease obligations, excluding fair value hedges	418	558
Total liabilities	755	765
Approximate fair value \| Significant unobservable inputs (Level 3)
Liabilities
Short-term borrowings	0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	0	0
Long-term debt and finance lease obligations, excluding fair value hedges	0	0
Total liabilities	$ 0	$ 0

Financial Instruments and Fai_9

Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - Accounts receivable, net - wholesaler	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Concentration of Risk
Number of principal customers	3
Geographic risk \| Principal US customers
Concentration of Risk
Concentrations risk (as a percent)	79%	81%

Financial Instruments and Fa_10

Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) - USD ($) $ in Millions	1 Months Ended		2 Months Ended	3 Months Ended
	Mar. 31, 2023	Jan. 31, 2023	Feb. 28, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 21, 2023	Dec. 06, 2023
Short-Term Borrowings [Line Items]
Short-term borrowings				$ 3		$ 0
Proceeds from Short-Term Debt				5,008	$ 0
Repayments of other short-term borrowings				5,005	$ 0
Commercial paper
Short-Term Borrowings [Line Items]
Short-term borrowings				$ 0		0
Short-Term Debt, Weighted Average Interest Rate, over Time				5.54%
Proceeds from Short-Term Debt				$ 1,700
Repayments of Short-Term Debt				$ 1,700
December 2023 Bridge Credit Facility
Short-Term Borrowings [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity								$ 9,000
364-day Term Loan Credit Agreement
Short-Term Borrowings [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity							$ 5,000
Term loan facilities
Debt and Credit Facilities [Line Items]
Long-Term Debt, Weighted Average Interest Rate, over Time				6.29%
Floating rate notes due 2023, refinanced \| Term loan facilities
Debt and Credit Facilities [Line Items]
Repayments of long-term debt		$ 1,000
2.8% senior notes due 2023 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt	$ 350
Stated interest rate (as a percent)				2.80%
Senior Notes Issued in 2024
Debt and Credit Facilities [Line Items]
Debt Issuance Costs, Gross				$ 99
Debt Instrument, Unamortized Discount				37
Senior Notes Issued in 2024 \| Senior notes
Debt and Credit Facilities [Line Items]
Aggregate principal amount of debt				15,000
Senior notes due 2027 \| Senior notes
Debt and Credit Facilities [Line Items]
Aggregate principal amount of debt				2,250
4.80% Senior Notes due 2029 \| Senior notes
Debt and Credit Facilities [Line Items]
Aggregate principal amount of debt				2,500
4.95% Senior Notes due 2031 \| Senior notes
Debt and Credit Facilities [Line Items]
Aggregate principal amount of debt				2,000
5.05% Senior Notes due 2034 \| Senior notes
Debt and Credit Facilities [Line Items]
Aggregate principal amount of debt				3,000
5.35% Senior Notes due 2044 \| Senior notes
Debt and Credit Facilities [Line Items]
Aggregate principal amount of debt				750
5.40% Senior Notes due 2054 \| Senior notes
Debt and Credit Facilities [Line Items]
Aggregate principal amount of debt				3,000
5.50% Senior Notes due 2064 \| Senior notes
Debt and Credit Facilities [Line Items]
Aggregate principal amount of debt				$ 1,500
December 2023 Term Loan Credit Agreement
Debt and Credit Facilities [Line Items]
Debt Instrument, Basis Spread on Variable Rate				0.975%
Short-Term Borrowings [Line Items]
Proceeds from Other Short-Term Debt				$ 5,000
Repayments of other short-term borrowings				5,000
Revolving Credit Facility
Short-Term Borrowings [Line Items]
Line of Credit Facility, Expiration Period	5 years		5 years
Line of Credit Facility, Maximum Borrowing Capacity			$ 4,000	5,000
Long-Term Line of Credit				$ 0		$ 0

Post-Employment Benefits (Detai

Post-Employment Benefits (Details) - USD ($) $ in Millions	3 Months Ended
Post-Employment Benefits (Details) - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023
Defined benefit plans
Defined benefit and other post-employment plans
Service cost	$ 72	$ 68
Interest cost	113	107
Expected return on plan assets	(197)	(180)
Amortization of prior service credit	0	0
Amortization of actuarial loss	13	4
Net periodic benefit cost	1	(1)
Other post-employment plans
Defined benefit and other post-employment plans
Service cost	11	8
Interest cost	10	9
Expected return on plan assets	0	0
Amortization of prior service credit	(9)	(9)
Amortization of actuarial loss	4	3
Net periodic benefit cost	$ 16	$ 11

Equity - Stock-Based Compensati

Equity - Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 348	$ 313
Tax benefit	60	55
After-tax compensation expense	288	258
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	22	20
Employee Benefits and Share-Based Compensation	31
Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	133	117
Employee Benefits and Share-Based Compensation	126
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	193	$ 176
Employee Benefits and Share-Based Compensation	$ 192

Equity - Stock Options (Details

Equity - Stock Options (Details) - Stock Options $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award
Stock options granted (in shares) \| shares	0.6
Weighted-average grant-date fair value of the stock options granted (in dollars per share) \| $ / shares	$ 31.53
Unrecognized compensation cost \| $	$ 11
Period for recognition of unrecognized compensation cost	2 years

Equity - RSUs and Performance S

Equity - RSUs and Performance Shares (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions		3 Months Ended
	Feb. 12, 2024	Mar. 31, 2024
RSUs and Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award
Shares granted (in shares)		4,900
Fair market value of awards vested (in dollars per share)		$ 175.97
Unrecognized compensation cost		$ 967
Period for recognition of unrecognized compensation cost		2 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award
Shares granted (in shares)	300

Equity - Cash Dividends (Detail

Equity - Cash Dividends (Details) - $ / shares	Feb. 15, 2024	Oct. 26, 2023	Sep. 08, 2023	Jun. 22, 2023	Feb. 16, 2023
Dividend Declared [Member]
Dividends Payable
Cash dividends declared per common share (in dollars per share)	$ 1.55	$ 1.55	$ 1.48	$ 1.48	$ 1.48

Equity - Stock Repurchase Progr

Equity - Stock Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Feb. 16, 2023
Equity, Class of Treasury Stock
Payment for shares repurchased	$ 1,324	$ 1,955
Remaining share repurchase authorization amount	$ 3,900
December 2018 Stock Repurchase Authorization
Equity, Class of Treasury Stock
Increase to existing stock repurchase authorization			$ 5,000
Shares repurchased (in shares)	5	10
Payment for shares repurchased	$ 959	$ 1,600

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance	$ 10,397	$ 17,287
Other comprehensive loss	(149)	(33)
Ending balance	8,047	13,303
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance	(1,106)	(1,513)
Other comprehensive income (loss) before reclassifications	(396)	194
Net losses (gains) reclassified from accumulated other comprehensive loss	0	0
Other comprehensive loss	(396)	194
Ending balance	(1,502)	(1,319)
Net investment hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance	65	464
Other comprehensive income (loss) before reclassifications	228	(202)
Net losses (gains) reclassified from accumulated other comprehensive loss	(21)	(22)
Other comprehensive loss	207	(224)
Ending balance	272	240
Pension and post-employment benefits
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance	(1,488)	(1,458)
Other comprehensive income (loss) before reclassifications	3	40
Net losses (gains) reclassified from accumulated other comprehensive loss	7	(2)
Other comprehensive loss	10	38
Ending balance	(1,478)	(1,420)
Cash flow hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance	224	308
Other comprehensive income (loss) before reclassifications	44	(10)
Net losses (gains) reclassified from accumulated other comprehensive loss	(14)	(31)
Other comprehensive loss	30	(41)
Ending balance	254	267
Accumulated other comprehensive income (loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance	(2,305)	(2,199)
Other comprehensive income (loss) before reclassifications	(121)	22
Net losses (gains) reclassified from accumulated other comprehensive loss	(28)	(55)
Other comprehensive loss	(149)	(33)
Ending balance	$ (2,454)	$ (2,232)

Equity - Amounts Reclassified O

Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing		$ 453	$ 454
Tax expense (benefit)		383	234
Total reclassifications, net of tax		(1,369)	(239)
Losses (gains) on foreign currency forward exchange contracts		4,094	3,986
Pension and post-employment benefits
Significant amounts reclassified out of each component of AOCI
Amortization of actuarial losses and other	[1]	8	(2)
Tax benefit		(1)	0
Total reclassifications, net of tax		7	(2)
Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Total reclassifications, net of tax		(14)	(31)
Reclassification out of accumulated other comprehensive loss \| Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Tax expense (benefit)		4	5
Total reclassifications, net of tax		(14)	(31)
Reclassification out of accumulated other comprehensive loss \| Net investment hedges \| Net investment hedging activities
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing	[2]	(27)	(28)
Tax expense (benefit)		6	6
Total reclassifications, net of tax		(21)	(22)
Foreign currency forward exchange contracts \| Reclassification out of accumulated other comprehensive loss \| Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Losses (gains) on foreign currency forward exchange contracts	[3]	(12)	(30)
Treasury rate lock agreements \| Reclassification out of accumulated other comprehensive loss \| Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing	[2]	$ (6)	$ (6)

[1] (b) Amounts are included in the computation of net periodic benefit cost (see Note 9). (c) Amounts are included in cost of products sold (see Note 8).

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Effective tax rate	22%	49%
U.S. statutory tax rate	21%	21%
Potential change in unrecognized tax benefits	$ 162

Legal Proceedings and Conting_2

Legal Proceedings and Contingencies (Details) $ in Millions	1 Months Ended	3 Months Ended
Legal Proceedings and Contingencies (Details) $ in Millions	Aug. 31, 2019 company	Mar. 31, 2024 USD ($) company lawsuit	Mar. 31, 2023 USD ($)	Mar. 31, 2024 claim	Mar. 31, 2024 claims	Jun. 30, 2022 USD ($)
Legal Proceedings and Contingencies
Income tax expense \| $		$ 383	$ 234
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits \| lawsuit		6
AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company	3
Bystolic antitrust litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company		6
Prescription drug abuse litigation
Legal Proceedings and Contingencies
Number of claims pending \| claim				580
Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Number of claims pending		165			130
Prescription drug abuse litigation in state courts \| Selling, general and administrative
Legal Proceedings and Contingencies
Litigation charge related to potential settlement \| $						$ 2,100
Tax court petition
Legal Proceedings and Contingencies
Income tax expense \| $			$ 572
Prescription Drug Abuse Litigation In State Courts In process of Being Dismissed
Legal Proceedings and Contingencies
Number of claims pending \| company		125

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended
Segment Information - Additional Information (Details)	Mar. 31, 2024 segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment Information - Disaggreg

Segment Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue
Total net revenues	$ 12,310	$ 12,225
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]	Total net revenues	Total net revenues
All other
Disaggregation of Revenue
Net revenues	$ 744	$ 691
Immunology \| Humira
Disaggregation of Revenue
Net revenues	2,270	3,541
Immunology \| Humira \| United States
Disaggregation of Revenue
Net revenues	1,771	2,948
Immunology \| Humira \| International
Disaggregation of Revenue
Net revenues	499	593
Immunology \| Skyrizi
Disaggregation of Revenue
Net revenues	2,008	1,360
Immunology \| Skyrizi \| United States
Disaggregation of Revenue
Net revenues	1,656	1,139
Immunology \| Skyrizi \| International
Disaggregation of Revenue
Net revenues	352	221
Immunology \| Rinvoq
Disaggregation of Revenue
Net revenues	1,093	686
Immunology \| Rinvoq \| United States
Disaggregation of Revenue
Net revenues	725	449
Immunology \| Rinvoq \| International
Disaggregation of Revenue
Net revenues	368	237
Hematologic Oncology \| Imbruvica
Disaggregation of Revenue
Net revenues	838	878
Hematologic Oncology \| Imbruvica \| United States
Disaggregation of Revenue
Net revenues	610	638
Hematologic Oncology \| Imbruvica \| International
Disaggregation of Revenue
Collaboration revenues	228	240
Hematologic Oncology \| Venclexta
Disaggregation of Revenue
Net revenues	614	538
Hematologic Oncology \| Venclexta \| United States
Disaggregation of Revenue
Net revenues	281	265
Hematologic Oncology \| Venclexta \| International
Disaggregation of Revenue
Net revenues	333	273
Hematologic Oncology \| Epkinly
Disaggregation of Revenue
Net revenues	27	0
Collaboration revenues	22	0
Hematologic Oncology \| Epkinly \| International
Disaggregation of Revenue
Net revenues	5	0
Hematologic Oncology \| Elahere \| United States
Disaggregation of Revenue
Net revenues	64	0
Aesthetics \| Botox Cosmetic
Disaggregation of Revenue
Net revenues	633	659
Aesthetics \| Botox Cosmetic \| United States
Disaggregation of Revenue
Net revenues	389	409
Aesthetics \| Botox Cosmetic \| International
Disaggregation of Revenue
Net revenues	244	250
Aesthetics \| Juvederm Collection
Disaggregation of Revenue
Net revenues	297	355
Aesthetics \| Juvederm Collection \| United States
Disaggregation of Revenue
Net revenues	106	122
Aesthetics \| Juvederm Collection \| International
Disaggregation of Revenue
Net revenues	191	233
Aesthetics \| Other Aesthetics
Disaggregation of Revenue
Net revenues	319	286
Aesthetics \| Other Aesthetics \| United States
Disaggregation of Revenue
Net revenues	281	246
Aesthetics \| Other Aesthetics \| International
Disaggregation of Revenue
Net revenues	38	40
Neuroscience \| Botox Therapeutic
Disaggregation of Revenue
Net revenues	748	719
Neuroscience \| Botox Therapeutic \| United States
Disaggregation of Revenue
Net revenues	611	587
Neuroscience \| Botox Therapeutic \| International
Disaggregation of Revenue
Net revenues	137	132
Neuroscience \| Vraylar
Disaggregation of Revenue
Net revenues	694	561
Neuroscience \| Vraylar \| United States
Disaggregation of Revenue
Net revenues	692	560
Neuroscience \| Vraylar \| International
Disaggregation of Revenue
Net revenues	2	1
Neuroscience \| Duodopa
Disaggregation of Revenue
Net revenues	115	118
Neuroscience \| Duodopa \| United States
Disaggregation of Revenue
Net revenues	25	25
Neuroscience \| Duodopa \| International
Disaggregation of Revenue
Net revenues	90	93
Neuroscience \| Ubrelvy
Disaggregation of Revenue
Net revenues	203	152
Neuroscience \| Ubrelvy \| United States
Disaggregation of Revenue
Net revenues	197	150
Neuroscience \| Ubrelvy \| International
Disaggregation of Revenue
Net revenues	6	2
Neuroscience \| Qulipta
Disaggregation of Revenue
Net revenues	131	66
Neuroscience \| Qulipta \| United States
Disaggregation of Revenue
Net revenues	128	66
Neuroscience \| Qulipta \| International
Disaggregation of Revenue
Net revenues	3	0
Neuroscience \| Other Neuroscience
Disaggregation of Revenue
Net revenues	74	79
Neuroscience \| Other Neuroscience \| United States
Disaggregation of Revenue
Net revenues	61	75
Neuroscience \| Other Neuroscience \| International
Disaggregation of Revenue
Net revenues	13	4
Eye Care \| Ozurdex
Disaggregation of Revenue
Net revenues	131	115
Eye Care \| Ozurdex \| United States
Disaggregation of Revenue
Net revenues	34	39
Eye Care \| Ozurdex \| International
Disaggregation of Revenue
Net revenues	97	76
Eye Care \| Lumigan/Ganfort
Disaggregation of Revenue
Net revenues	91	130
Eye Care \| Lumigan/Ganfort \| United States
Disaggregation of Revenue
Net revenues	29	63
Eye Care \| Lumigan/Ganfort \| International
Disaggregation of Revenue
Net revenues	62	67
Eye Care \| Alphagan/Combigan
Disaggregation of Revenue
Net revenues	59	71
Eye Care \| Alphagan/Combigan \| United States
Disaggregation of Revenue
Net revenues	15	28
Eye Care \| Alphagan/Combigan \| International
Disaggregation of Revenue
Net revenues	44	43
Eye Care \| Restasis
Disaggregation of Revenue
Net revenues	57	92
Eye Care \| Restasis \| United States
Disaggregation of Revenue
Net revenues	44	79
Eye Care \| Restasis \| International
Disaggregation of Revenue
Net revenues	13	13
Eye Care \| Other Eye Care
Disaggregation of Revenue
Net revenues	200	200
Eye Care \| Other Eye Care \| United States
Disaggregation of Revenue
Net revenues	105	110
Eye Care \| Other Eye Care \| International
Disaggregation of Revenue
Net revenues	95	90
Other Key Products \| Mavyret
Disaggregation of Revenue
Net revenues	349	364
Other Key Products \| Mavyret \| United States
Disaggregation of Revenue
Net revenues	144	171
Other Key Products \| Mavyret \| International
Disaggregation of Revenue
Net revenues	205	193
Other Key Products \| Creon \| United States
Disaggregation of Revenue
Net revenues	285	305
Other Key Products \| Linzess/Constella
Disaggregation of Revenue
Net revenues	266	259
Other Key Products \| Linzess/Constella \| United States
Disaggregation of Revenue
Net revenues	257	251
Other Key Products \| Linzess/Constella \| International
Disaggregation of Revenue
Net revenues	$ 9	$ 8